The Centers for Disease Control and Prevention and the U.S. Food and Drug Administration recommended use of Johnson & Johnson’s Janssen COVID-19 Vaccine resume in the U.S. after a temporary pause.

The CDC said reports suggested the Johnson & Johnson vaccine had an increased risk of a rare adverse event called thrombosis with thrombocytopenia syndrome (TTS).

Most reports of this serious condition, which involves blood clots with low platelets, have been in adult women younger than 50 years old, according to the CDC.

However, the CDC said a review of available data showed that the J&J COVID-19 vaccine’s known and potential benefits outweigh its known and potential risks.

Even though the two agencies recommend the use of the J&J vaccine, the CDC said women younger than 50 years old especially should be aware of the rare but increased risk of this adverse event.

The CDC said the women should know about other available COVID-19 vaccine options in which this risk has not been seen.

Both the CDC and FDA said they will continue to monitor the safety of all COVID-19 vaccines and advise that you seek medical care right away if you develop any of the symptoms of TTS after receiving a COVID-19 vaccine.

If you have any questions or concerns, call your doctor, nurse, or clinic.